Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB₄: possible fallout on non-medical switching' by Cantini and Benucci

Bente Glintborg^{1

2}, Anne Gitte Loft^{3

4}, Emina Omerovic⁵, Oliver Hendricks⁶, Asta Linauskas⁷, Jakob Espesen⁸, Kamilla Danebod², Dorte Vendelbo Jensen², Henrik Nordin⁹, Emil Barner Dalgaard¹⁰, Stavros Chrysidis¹¹, Salome Kristensen¹², Johnny Lillelund Raun¹³, Hanne Lindegaard¹⁴, Natalia Manilo¹⁵, Susanne Højmark Jakobsen¹⁶, Inger Marie Jensen Hansen¹⁶, Dorte Dalsgaard Pedersen¹⁶, Inge Juul Sørensen¹⁷, Lis Smedegaard Andersen¹⁸, Jolanta Grydehøj¹⁹, Frank Mehnert²⁰, Niels Steen Krogh²¹, Merete Lund Hetland^{22

17}

Affiliations

¹ The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glostrup, Denmark glintborg@dadlnet.dk.
² Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
³ Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
⁴ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁵ Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, København, Denmark.
⁶ Kong Christian X's Gigthospital, Gråsten, Denmark.
⁷ Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark.
⁸ Department of Rheumatology, Vejle Hospital, Vejle, Denmark.
⁹ Department of Rheumatology, Zealand University Hospital, Køge, Denmark.
¹⁰ Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark.
¹¹ Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark.
¹² Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.
¹³ Department of Rheumatology, Sygehus Lillebælt, Fredericia, Denmark.
¹⁴ Department of Rheumatology, Odense University Hospital, Odense, Denmark.
¹⁵ Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark.
¹⁶ Department of Rheumatology, OUH, Svendborg Hospital, Svendborg, Denmark.
¹⁷ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
¹⁸ Department of Internal Medicine, Rønne Hospital, Rønne, Denmark.
¹⁹ Department of Rheumatology, Holstebro Hospital, Holstebro, Denmark.
²⁰ Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
²¹ Zitelab, Copenhagen, Denmark.
²² The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glostrup, Denmark.

PMID: 30573653
DOI: 10.1136/annrheumdis-2018-214788

Comment

Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB₄: possible fallout on non-medical switching' by Cantini and Benucci

Bente Glintborg et al. Ann Rheum Dis. 2020 Feb.

. 2020 Feb;79(2):e14.

doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20.

Authors

Affiliations

¹ The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glostrup, Denmark glintborg@dadlnet.dk.
² Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
³ Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
⁴ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁵ Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, København, Denmark.
⁶ Kong Christian X's Gigthospital, Gråsten, Denmark.
⁷ Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark.
⁸ Department of Rheumatology, Vejle Hospital, Vejle, Denmark.
⁹ Department of Rheumatology, Zealand University Hospital, Køge, Denmark.
¹⁰ Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark.
¹¹ Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark.
¹² Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.
¹³ Department of Rheumatology, Sygehus Lillebælt, Fredericia, Denmark.
¹⁴ Department of Rheumatology, Odense University Hospital, Odense, Denmark.
¹⁵ Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark.
¹⁶ Department of Rheumatology, OUH, Svendborg Hospital, Svendborg, Denmark.
¹⁷ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
¹⁸ Department of Internal Medicine, Rønne Hospital, Rønne, Denmark.
¹⁹ Department of Rheumatology, Holstebro Hospital, Holstebro, Denmark.
²⁰ Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
²¹ Zitelab, Copenhagen, Denmark.
²² The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glostrup, Denmark.

PMID: 30573653
DOI: 10.1136/annrheumdis-2018-214788

No abstract available

Keywords: DMARDs (biologic); anti-tnf; epidemiology; outcomes research.

PubMed Disclaimer

Conflict of interest statement

Competing interests: BG: AbbVie, Biogen, Pfizer, MSD. MLH: Orion, BMS, AbbVie, Biogen, Pfizer, MSD, Celltrion. IMJH: Roche. AGL: AbbVie, MSD, Novartis, Pfizer, Roche, UCB. OH: AbbVie, Roche, Novartis. HN: AbbVie, Novartis, Medac. LSA: Pfizer.

Comment on

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5. Ann Rheum Dis. 2019. PMID: 30396903
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.
Cantini F, Benucci M. Cantini F, et al. Ann Rheum Dis. 2020 Feb;79(2):e13. doi: 10.1136/annrheumdis-2018-214757. Epub 2018 Nov 28. Ann Rheum Dis. 2020. PMID: 30487149 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB₄: possible fallout on non-medical switching' by Cantini and Benucci

Affiliations

Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB₄: possible fallout on non-medical switching' by Cantini and Benucci

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources